PD-1/PD-L1 blockade can produce durable tumor control in many patients, but primary, adaptive, and acquired resistance remain frequent. Traditional categorizations of resistance often catalogue mechanisms by cellular compartment, which can obscure how tumors coordinate adaptation to therapy. To address this, the authors present immune-pressure redistribution as a treatment-oriented framework that complements existing concepts such as cancer immunoediting by asking where therapeutic immune pressure is diverted after checkpoint release.
The framework aims to reframe resistance as a redistribution of immune pressure across tumor-intrinsic and host compartments, thereby informing biomarker selection and therapeutic design that match the dominant topology of escape.
Resistance is organized into three coupled routes: (1) transfer into tumor-intrinsic escape, (2) weakening of productive immunity, and (3) unloading into host or non-tumor compartments. These routes are not mutually exclusive; tumors may employ multiple trajectories simultaneously or sequentially, creating a coordinated pattern of immune evasion after PD-1/PD-L1 blockade.
Understanding which route predominates in an individual patient could guide topology-specific interventions designed to restore effective immune pressure while limiting compensatory escape and treatment toxicity.
The transfer route describes processes that convert immunologic pressure into tumor cell–intrinsic adaptations. Key mechanisms include loss of antigen presentation machinery, defects in interferon-response pathways, oncogenic signaling rewiring, and lineage plasticity. Each of these changes reduces tumor 'visibility' or susceptibility to immune-mediated killing following checkpoint inhibition.
These tumor-intrinsic changes are presented as a major route by which initial immune pressure is effectively redirected into a state in which tumor cells evade recognition or resist cytotoxic effector functions.
The weakening route captures alterations that diminish the generation, maintenance, or functionality of anti-tumor immune responses. Examples include defective priming of T cells, progression to terminal T-cell differentiation or exhaustion, engagement of compensatory immune checkpoints, metabolic constraints within the tumor microenvironment, and chronic cytokine signaling that blunts effector activity.
This route emphasizes failures not at the tumor cell level but within the immune response itself, where the quality and sustainability of T-cell responses are compromised despite checkpoint blockade.
The unloading route describes diversion of immune pressure away from tumor cells into other compartments of the host. This includes stromal barriers, vascular factors, myeloid and regulatory cell populations, microbial influences, and systemic host factors. In these contexts, immune responses may be sequestered, diverted, or functionally suppressed, decreasing effective pressure on malignant cells despite therapy.
By framing these processes as unloading, the authors highlight how non-malignant host components can absorb or deflect therapeutic immune pressure and thereby contribute to resistance.
The review integrates clinically validated mechanisms with emerging evidence. Two notable concepts emphasized are the temporal duality of interferon-JAK signaling and the importance of tumor-draining lymph nodes in sustaining progenitor-exhausted T cells. The interferon-JAK axis has context-dependent effects, and its timing and downstream consequences can contribute both to anti-tumor activity and to resistance. Tumor-draining lymph nodes are highlighted as critical sites for maintaining T-cell progenitors that support long-term antitumor immunity.
These concepts illustrate the dynamic and time-dependent nature of immune responses to checkpoint blockade and the potential pitfalls of interventions that do not account for temporal or spatial context.
The authors note the limited translation to date of several targeted approaches intended to overcome resistance, including inhibitors or modulators of TIGIT, IDO1, TGF-β, and CSF-1R. While these targets have biological rationale and preclinical support, clinical results have been modest or inconsistent, underscoring the need for refined strategies that match interventions to the dominant resistance topology.
This observation supports the argument for better biomarker selection and topology-driven therapeutic design rather than uniform combination escalation.
To operationalize immune-pressure redistribution clinically, the authors propose a biomarker-guided strategy that integrates multiple dimensions: tumor visibility (e.g., antigen presentation and interferon response), immune-cell state (progenitor versus terminal exhaustion), spatial architecture (tumor and stromal distribution), systemic inflammation, and early treatment dynamics. Combining these features could help identify which resistance route predominates for a patient and thus inform selection of topology-matched interventions.
The review emphasizes that biomarker integration should be dynamic, incorporating early treatment responses and temporal changes rather than relying solely on baseline measurements.
Based on the immune-pressure redistribution framework, the authors advocate for topology-matched combination therapies and adaptive sequencing rather than blanket escalation of immunotherapy. The goal is to restore productive immune pressure in the compartment where it has been lost or diverted while avoiding interventions that provoke compensatory escape or excess toxicity.
This approach favors rational, biomarker-informed selection of agents designed to address tumor-intrinsic defects, augment immune priming and function, or relieve stromal and systemic impediments to immune activity depending on the identified topology.
Immune-pressure redistribution offers a treatment-centered lens on resistance to PD-1/PD-L1 blockade that complements immunoediting. By classifying resistance into transfer, weakening, and unloading routes, and by proposing a biomarker-driven strategy to detect dominant topologies, the framework aims to guide topology-matched combinations and adaptive therapeutic sequencing. The review synthesizes validated mechanisms and emerging evidence to inform future therapeutic design and biomarker development.
Note: Details beyond the abstract—such as specific trial results, quantitative biomarker thresholds, or comprehensive lists of supporting studies—were not reported in the source abstract and are therefore not included here.